Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib vs Temozolomide in Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733Phase 3Active, not recruiting
- Sponsor
- Ivy Brain Tumor Center
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of niraparib in glioblastoma (GBM), sponsored by Ivy Brain Tumor Center. Started Jun 2024; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06388733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388733.